Lupin Limited has informed the Exchange regarding a press release dated July 17, 2025, titled "Lupin Achieves GMP Certification from TGA Australia for Dabhasa API Facility".
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lupin Limited announced that its API manufacturing facility in Dabhasa, Gujarat, operated by wholly owned subsidiary Lupin Manufacturing Solutions (LMS), has received Good Manufacturing Practice (GMP) certification from Australia's medicines regulator, the Therapeutic Goods Administration (TGA). LMS specializes in API manufacturing and pharmaceutical CDMO services. The certification validates the facility's manufacturing quality standards and compliance, supporting Lupin's global expansion plans. Australia is one of over 100 markets where Lupin distributes its products.
This is a positive development for Lupin as it enables the Dabhasa facility to supply APIs to the Australian market and strengthens LMS's credibility in the global CDMO space. It may open new revenue opportunities in Australia and reinforce investor confidence in the company's quality and compliance standards, though no immediate financial impact was disclosed.